Literature DB >> 193659

Evaluation of 3 hour metyrapone test in children and adolescents.

S Leisti.   

Abstract

An evaluation of a new 3 h metyrapone test is presented. The test consists of one oral dose of metyrapone given at 08.00-09.00 hours, and determination of plasma deoxycortisol from a single capillary blood sample taken 3 h later. The test has been assessed in children and adolescents in conjunction with a 5 day metyrapone test, insulin test, vasopressin test, and ACTH test in forty-five reference subjects, in thirty-six hypopituitary subjects with normal or deficient ACTH secretion, in three subjects with primary adrenocortical disease and in ten subjects prior to and after pharmacological prednisone medication. During the first hour after metyrapone the plasma cortisol level decreased to almost the low level maintained for the rest of the 3 h period. The plasma deoxycortisol concentration was basally less than or equal to 35 nmol/l and increased continuously during the 3 h period to the mean level of 299 (95% confidence interval 133-669) nmol/l in the reference subjects. The new test proved to be as accurate as the insulin test in detecting ACTH deficiency. No significant rise was observed in the plasma somatotrophin (GH) level in those children who had a normal GH response to insulin hypoglycaemia.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 193659     DOI: 10.1111/j.1365-2265.1977.tb02016.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  4 in total

1.  Idiopathic nephrotic syndrome: prevention of early relapse.

Authors:  S Leisti; O Koskimies; J Perheentupa; J Vilska; N Hallman
Journal:  Br Med J       Date:  1978-04-08

2.  Short-term kinetics of serum adrenal steroids and plasma ACTH after a single dose of metyrapone in man.

Authors:  M Schöneshöfer; B Schefzig; S Arabin
Journal:  J Endocrinol Invest       Date:  1980 Jul-Sep       Impact factor: 4.256

3.  Mechanism of adrenal suppression by high-dose medroxyprogesterone acetate in breast cancer patients.

Authors:  H van Veelen; P H Willemse; D T Sleijfer; E van der Ploeg; W J Sluiter; H Doorenbos
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Alveolar hypoventilation treated with medroxyprogesterone.

Authors:  J Milerad; H Lagercrantz; O Löfgren
Journal:  Arch Dis Child       Date:  1985-02       Impact factor: 3.791

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.